Korea S.E.
03:30:00 14/05/2024 am IST
5-day change
1st Jan Change
17,160
KRW
+1.00%
-1.15%
+0.35%
Jeil Pharma Holdings Inc acquired 13.53% stake in Jeil Pharmaceutical Co.,Ltd.
Jeil Pharma Holdings Inc (KOSE:A002620) acquired 13.53% stake in Jeil Pharmaceutical Co.,Ltd (KOSE:A271980) on May 2, 2018.
Jeil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
12/23/12
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
13/22/13
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
13/22/13
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
13/22/13
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
13/22/13
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
13/22/13
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on December 10, 2020, has expired with 42,941 shares, representing 0.29% for KRW 1,521.88 million.
09/22/09
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till December 9, 2022.
09/22/09
CI
Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea
13/22/13
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till June 9, 2022.
09/21/09
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on December 10, 2020, has expired.
09/21/09
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till December 09, 2021.
09/21/09
CI
Rockwell Medical, Inc. Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd
01/21/01
CI
Jeil Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.
10/20/10
CI
Jeil Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
10/20/10
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on May 16, 2019.
15/20/15
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on May 16, 2019, has expired with 84,920 shares, representing 0.58% for KRW 2,707.67 million.
15/20/15
CI
Jeil Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.
16/19/16
CI
Jeil Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
16/19/16
CI
Jeil Pharma Holdings Inc completed the acquisition of additional 35.2% stake in Jeil Pharmaceutical Co.,Ltd for approximately KRW 250 billion.
16/18/16
CI
Jeil Pharma Holdings Inc made an offer to acquire an additional 47.6% stake in Jeil Pharmaceutical Co.,Ltd for approximately KRW 490 billion.
02/18/02
CI
Jeil Pharma Holdings Inc acquired 13.53% stake in Jeil Pharmaceutical Co.,Ltd.
02/18/02
CI
Jeil Pharmaceutical Co.,Ltd(KOSE:) added to S&P Global BMI Index
17/17/17
CI
Jeil Pharmaceutical Co., Ltd. announced the spin-off of its pharmaceuticals manufacturing and sales business.
16/17/16
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
JEIL PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company provides anti-inflammatory painkillers, anticancer drugs, gastritis drugs, antibiotics, ulcer treatments, antidepressant drugs, pollakisuria and incontinence treatments, impetigo drugs, septicemia treatments, hyperlipidemia treatments, peripheral neuropathic pain drugs, hypertension drugs and others. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
+0.35% 183M +21.28% 44.4B +24.60% 23.03B +19.22% 15.14B +12.87% 13.12B +44.67% 11.85B -8.33% 6.99B -0.05% 6.79B -8.87% 5.73B +12.22% 5.52B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
JEIL PHARMACEUTICAL CO.,LTD 
